Form 4: Provectus Biopharmaceuticals Director Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

Director Edward Pershing reports the conversion of a convertible note into Series D-1 Convertible Preferred Stock of Provectus Biopharmaceuticals.

Summary

• On April 6, 2024, Edward Pershing, a director of Provectus Biopharmaceuticals, reported a transaction involving the conversion of an 8% unsecured convertible promissory note into 47,190 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock.
• Following the transaction, Pershing beneficially owns 1,140,952 shares of Common Stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to a previously announced financing. It doesn't contain information that would significantly shift investor sentiment.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Key Dates